|Dr. Fraser Murray, PhD, MBA||
Fraser has over 20 years experience in the pharmaceutical industry, ranging from small start up biotech to large multinational pharmaceutical companies. Fraser began his career with Merck & Co. at their Neuroscience Research Centre in the UK working on a range of neurodegeneration and psychiatry projects. He then moved to AstraZeneca's Respiratory and Inflammation research group where he worked on osteoarthritis, rheumatoid arthritis and pain. In 2011 he took a role with Shire where he was a Senior Director and had responsibility for Discovery Biology for Shire's CNS and GI discovery portfolio. In addition to his role with Arisgen, Fraser is also Vice President of Biology at Calcico Therapeutics, a venture backed spin out from the University of Oxford. Fraser is also a Co-founder and Director of Polleo Pharma, a spin out company from Shire looking to develop leading therapies for behavioural health disorders. Fraser obtained his BSc in Immunology and Pharmacology from the University of Strathclyde, his PhD in Neuropharmacology from the School of Pharmacy, University of London and his MBA from Manchester Business School, University of Manchester.
|Frédéric Preitner, PhD||
Frédéric Preitner holds a Ph.D. in Medical Biochemistry (University of Geneva) in the field of obesity. He then performed a post-doctoral training in the field of insulin secretion at University of Lausanne, and a second post-doctoral training in the field of Insulin action at BIDMC/Harvard Medical School, Boston. Since September 2006 he is developping and running the Mouse metabolic Facility at University of Lausanne. His team has performed in vivo validation of Ariscrown formulations since August 2007. www.unil.ch/mef/
|Arduino Arduini, PhD||
Graduated in Medicine cum laude (1980) at University of “G. D’Annunzio” School of Medicine, Chieti, Italy.
|Dr. Mark Graham, BSc, PhD, FBTS||
Mark has over 27 years experience of Pharmaceutical Toxicology, 2 Years as an independent Consultant.
Formerly Global Discipline Leader of Discovery Toxicology in AstraZeneca
Extensive Experience of Toxicology in all phases of Pharmaceutical Discovery and Development in several therapeutic areas
Extensive experience of investigative problem solving Toxicology
Experienced in management of alliances and collaborations
Active in Toxicology research and via collaborations with several Universities
Awarded Fellowship of the British Toxicology Society
Member of the UK Government's Committee on Toxicity
PhD in Xenobiotic metabolism / Toxicology from Newcastle University